Owlet, the pioneer of smart baby monitoring, has received clearance from the U.S. Food and Drug Administration (FDA) for its latest product, BabySat™. This marks the first medical pulse-oximetry device with a wire-free sock design. Owlet, known for its expertise in infant health data, aims to combine its consumer-oriented approach with hospital-grade monitoring accuracy.
The significance of innovation in the baby care space is underscored by the ongoing challenges faced by caregivers and healthcare providers. With approximately 92 million infant care visits within a child's first four years of life, the availability of hospital beds and the quality of care are strained.
BabySat addresses these challenges by bringing real-time, medical-grade infant monitoring into the home under the supervision of a physician. Available through prescription, the device utilizes pulse oximetry technology to provide a real-time display of a baby's heart rate and oxygen saturation level (SpO2). Parents are alerted when these readings fall outside the prescribed ranges. Equipped with this information and under medical supervision, caregivers can confidently provide at-home care, thereby reducing the burden on medical resources.
The introduction of the FDA-cleared BabySat device expands Owlet's existing portfolio of consumer products designed to bring peace of mind to caregivers. The product will be available in the United States and is expected to launch later this year. Owlet, founded by a team of parents in 2012, aims to empower parents by providing them with timely information and insights, fostering confidence and peace of mind. The company's digital parenting platform strives to offer real-time data and insights, enabling parents to feel calmer and more assured. Owlet believes in providing every parent with peace of mind and the opportunity to be well-rested, while also working towards the goal of every child living a long, happy, and healthy life by developing products to support this vision.
